Prognostic Significance of Host‐ and Tumor‐Related Factors in Patients with Gastric Cancer

Mohri, Yasuhiko; Tanaka, Kouji; Ohi, Masaki; Yokoe, Takeshi; Miki, Chikao; Kusunoki, Masato

doi:10.1007/s00268-009-0302-1

Cited by 114 publications

(97 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Relative lymphopenia on the other hand reflect the cortisol-induced stress response [25]. In various studies the NLR correlates with markers of a proinflammatory state and an elevated NLR is associated with an increase in vascular end-points and with a worse outcome after oncologic surgery [26][27][28]. Also it has been associated with a high mortality in critical limb ischemia patients and has been found to be a prognostic marker in patients with cancer and coronary artery disease [25,29,31].…”

Section: Discussionmentioning

confidence: 99%

Neutrophil to Lymphocyte Ratio May Be a Diagnostic Marker for Prosthetic Joint Infection

2016

Ann Clin Anal Med

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Neutrophil to Lymphocyte Ratio May Be a Diagnostic Marker for Prosthetic Joint Infection

2016

Ann Clin Anal Med

View full text Add to dashboard Cite

show abstract

“…An appropriate decision may result in better survival or better quality of life for patients. At present, the TNM staging remains the most common and effective way to predict the prognosis of gastric cancer before treatment (Mohri et al, 2010). However, most patients have developed advanced tumor or metastasis at the time of diagnosis, and the prognoses of patients in the same stage are often poles apart.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Role of C-reactive Protein in Gastric Cancer: A Meta-analysis

Yu²,

Zhang

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: A number of studies have investigated the association between increased pretreatment serum C-reactive protein (CRP) levels and the prognosis of gastric cancer. However, due to the inconsistent results, whether the serum CRP level can be a prognostic factor in primary gastric cancer remains controversial. Methods: We searched Medline, PubMed, Embase and the Cochrane Central Register of Controlled Trials for relevant high-quality reports. A meta-analysis was carried out using the included studies to assess the association between pretreatment serum CRP level and overall survival (OS) in patients with gastric cancer. Correlation analyses were conducted to evaluate the relationship between serum CRP and tumor characteristics such as tumor node metastasis (TNM) stage and recurrence. Results: Twelve reports involving 2,597 patients with gastric cancer were included. Primary meta-analysis indicated a significant association between elevated CRP level and poor OS (HR 1.77, 95% CI 1.56-2.00). Subgroup analyses showed no single factor could alter the primary results when we divided the included studies by "number of patients", "max follow-up period", "TNM stage", "treatment" and "cut-off value". Correlation analyses showed that serum CRP level was significantly related to TNM stage (OR 2.96, 95% CI 2.22-3.93) and tumor recurrence (OR 1.81, 95% CI 1.21-2.71). Conclusions: We demonstrated that increased pretreatment serum CRP level (≥10mg/L) was significantly associated with poor prognosis in gastric cancer patients, either in early or advanced stages.

show abstract

“…Serum cholinesterase (ChE) in combination with ALB is one of the main indices of the protein-synthetic ability of the liver (13)(14)(15)(16)(17)(18)(19). Unlike ALB level, which is influenced by various factors such as bleeding, inflammation, chronic renal diseases or branched chain amino acid administration, the serum ChE level simply reflects the background liver function (13)(14)(15)(16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

“…Unlike ALB level, which is influenced by various factors such as bleeding, inflammation, chronic renal diseases or branched chain amino acid administration, the serum ChE level simply reflects the background liver function (13)(14)(15)(16)(17)(18)(19). Serum ChE level has been reported to be an important prognostic factor in malignancies other than HCC, including gastric and pancreatic cancers treated with systemic chemotherapy (13)(14)(15)(16)(17). In addition, serum ChE level has been reported as a prognostic factor in cholangiocellular carcinoma patients treated with radiotherapy (18), patients with recurrent HCC after hepatectomy (20), and in liver transplantation recipients with chronic end-stage liver disease (21).…”

Section: Introductionmentioning

confidence: 99%

Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib

Takeda

Nishikawa

Iguchi

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The value of serum cholinesterase (ChE) level as a predictive marker in sorafenib therapy for advanced hepatocellular carcinoma (HCC) has not yet been investigated. The present retrospective study therefore analyzed the impact of the serum ChE level in 93 patients with advanced HCC treated with sorafenib. Patients were categorized into two groups: group A with pretreatment serum ChE ≥140 IU/l (n=46) and group B with pretreatment serum ChE <140 IU/l (n=47). The correlation between clinicopathological findings, including serum ChE level, and overall survival (OS) and liver damage during sorafenib therapy was investigated. The median OS of the patients was 275 days, while OS was markedly higher in group A compared to group B (P=0.002). In 70 Child-Pugh A patients, serum ChE level was a significant prognostic predictor in multivariate analysis [P=0.019, hazard ratio (HR) =2.612; 95% confidence interval (CI), 1.174-5.810]. During sorafenib treatment, 22 patients developed liver dysfunction of grade 3 or higher. Only two group A patients (4.3%) developed liver dysfunction, compared to 20 group B patients (42.6%) (P<0.001). Multivariate analysis demonstrated that the pretreatment serum ChE level was the strongest predictor of liver damage (P= 0.002, HR= 0.061, 95% CI: 0.010-0.373), indicating serum ChE <140 IU/l to be the only independent predictor associated with severe liver function damage during sorafenib treatment in 70 patients with grade A Child-Pugh (P= 0.016; HR= 0.122; 95% CI, 0.022-0.676). In conclusion, lower serum ChE level is a significant predictor of poor prognosis and severe liver damage in HCC patients treated with sorafenib. Advanced HCC patients with lower serum ChE levels, including those with a Child-Pugh A pretreatment liver function score, should be given sorafenib therapy with caution.

show abstract

Prognostic Significance of Host‐ and Tumor‐Related Factors in Patients with Gastric Cancer

Abstract: This model based on N/L ratio, tumor size, and clinical T grouping before treatment offers a very informative scoring system for predicting prognosis of gastric cancer.

Cited by 114 publications

References 32 publications

Neutrophil to Lymphocyte Ratio May Be a Diagnostic Marker for Prosthetic Joint Infection

Neutrophil to Lymphocyte Ratio May Be a Diagnostic Marker for Prosthetic Joint Infection

Prognostic Role of C-reactive Protein in Gastric Cancer: A Meta-analysis

Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib

Contact Info

Product

Resources

About